<DOC>
	<DOCNO>NCT01189526</DOCNO>
	<brief_summary>This study design evaluate efficacy intravitreal Ranibizumab comparison macular laser photocoagulation treatment macular edema secondary branch retinal vein occlusion . Characteristics study 1 . Multicenter , randomize clinical trial . ( intravitreal Ranibizumab 0.5mg injection vs. macular laser photocoagulation ) 2 . After 48 week follow , functional change ( visual acuity ) anatomical change ( central retinal thickness ) would evaluate</brief_summary>
	<brief_title>Comparison Intravitreal Ranibizumab Macular Laser Photocoagulation ME Following Branch Retinal Vein Occlusion ( BRVO )</brief_title>
	<detailed_description />
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Symptom duration &lt; 6 Months , &gt; 4 week Visual acuity le 20/40 ( 73 letter ) 20/400 ( 19 letter ) ETDRS chart OCT center involve retinal thickening : &gt; 250 micrometer clear medium well control hypertension ( &lt; 140/90mmHg ) diabetes ( 6.5 &lt; HbA1c &lt; 9.5 ) willing return schedule visit uveitis , NVG , exudative AMD , diabetic retinopathy , IrvineGass syndrome , OIS malignancy previous treatment history laser photocoagulation , intravitreal injection drug , vitrectomy vitreomacular traction epiretinal membrane intraocular surgery study eye within 6 month uncontrolled glaucoma ( &gt; 30mmHg antiglaucoma medication ) optic neuropathy , amblyopia A condition opinion investigator would preclude patient 's participation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Branch retinal vein occlusion</keyword>
	<keyword>macular edema</keyword>
	<keyword>intravitreal injection</keyword>
	<keyword>ranibizumab</keyword>
</DOC>